Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase 3 Clinical Study for the Treatment of Cold Sore (LIP)

This study has been completed.
Information provided by (Responsible Party):
Onxeo Identifier:
First received: October 8, 2008
Last updated: November 21, 2012
Last verified: November 2012
To demonstrate the efficacy of a single dose of acyclovir Lauriad® 50mg muco-adhesive buccal tablet versus a single dose of matching placebo on the primary vesicular lesion of cold sore.

Condition Intervention Phase
Herpes Labialis
Drug: Acyclovir Lauriad
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double-Blind, Single Dose, One-Day Early Administration, Multicentre Study Comparing the Efficacy and Safety of Acyclovir Lauriad® 50 mg Muco-adhesive Buccal Tablet to Matching Placebo, in the Treatment of Herpes Labialis in Immunocompetent Patients.

Resource links provided by NLM:

Further study details as provided by Onxeo:

Primary Outcome Measures:
  • Time to Healing (TTH) of Vesicular Primary Lesion [ Time Frame: Assessed from time of treatment initiation through Day 14 ]
    Healing was defined as the loss of crust (erythema may be present) as assessed by the investigator. TTH was the time from treatment initiation to healing as defined above and was assessed from the time of treatment initiation through Day 14. The primary vesicular lesion was the first developed lesion located on the lip and was not to have extended more than 1 cm outside the lip.

Secondary Outcome Measures:
  • Abortion of Primary Lesions [ Time Frame: Assessed from the time of treatment initiation through Day 14 ]
    Aborted lesions were defined as herpetic lesions preceded by prodromal symptoms that did not progress beyond the papule stage.

  • TTH of Non-primary Lesions (Aborted Lesions Excluded) [ Time Frame: Assessed from the time of treatment initiation through Day 14 ]
    TTH of non-primary lesions was defined as the time from treatment initiation to healing of all non-primary vesicular lesions. Non-primary lesions were those that developed in addition to and/or in 1 or more days after the primary vesicular lesion and that were located at least 1 cm from the primary lesion. Aborted lesions were not included in this parameter. TTH was to be assessed by the investigator.

  • Duration of Episode (DOE) [ Time Frame: Assessed from initiation of treatment to Day 14 ]
    For patients who experienced a vesicular lesion, DOE was defined as the time from treatment initiation to healing of primary and secondary vesicular lesions (loss of crust). For subjects whose primary and secondary lesions were not vesicular in nature, DOE was defied as the time from treatment initiation to return to normal skin or to cessation of symptoms, whichever came last.

  • Time to Cessation of Symptoms [ Time Frame: Assessed from time of treatment initiation through Day 14 ]
    Time to cessation of symptoms was defined as the time from treatment initiation to cessation of all symptoms: pain, burning, itching, tingling, tenderness and discomfort. It was to be assessed by the investigator.

  • TTH of Aborted Primary Lesions [ Time Frame: Assessed from time of treatment initiation through Day 14 ]
    TTH of aborted primary lesions was defined as the time from treatment initiation to healing of the primary lesion (erythema or papule) or cessation of symptoms, whichever came last. It was to be assessed by the investigator.

  • Time to Recurrence of Non-aborted Lesions During 9-month Follow-up [ Time Frame: From time of initial healing through the 9-month follow-up ]
    Time to recurrence was the time from the healing of all lesions of the initial episode to the occurrence of new lesions.

  • Patient Incidence of Recurrence of Non-aborted Lesions During 9-month Follow-up [ Time Frame: From time of initial healing through the 9-month follow-up ]
    Recurrence was the occurrence of new lesions and was evaluated in a subgroup of patients who agreed to record recurrences during the 9-month follow-up period.

  • Symptom Intensity (Visual Analogue Scale [VAS]) [ Time Frame: Assessed on Days 1, 3, 5, 7 and 14 (or within 24 hours of healing) ]
    Patients were asked to place a tick mark on a 10 centimeter VAS indicating their symptom intensity. Scale ratings ranged from a minimum of 0 (none at all) to a maximum of 10 (worst possible). The location of the tick mark from "0" was measured in millimeters (0 - 100) and recorded.

  • Patient Satisfaction With Treatment [ Time Frame: Assessed on Day 14 (or within 24 hours of healing) ]
    At the end of study (Day 14 [or within 24 hours of healing]), patients were asked whether they were satisfied with treatment (yes/no).

  • Patient Assessment of Efficacy of the Treatment [ Time Frame: Assessed on Day 14 (or within 24 hours of healing) ]
    At the end of study (Day 14 [ or within 24 hours of healing]), patients were asked to rate efficacy of treatment using a 4-point scale (inactive, mildly active, moderately active, or very active).

Enrollment: 1727
Study Start Date: May 2007
Study Completion Date: August 2009
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Acyclovir Lauriad 50mg
Drug: Acyclovir Lauriad
50 mg muco-adhesive buccal tablets, single application on the gum
Placebo Comparator: 2 Drug: Placebo
50 mg muco-adhesive buccal tablets, single application on the gum


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • History of recurrent herpes labialis lesions where:

    • At least 50% of previous episodes produced classical lesions to the vesicular stage (i.e. episodes that progressed through macula, papule, vesicle, crust and healed);
    • Prodromal symptoms (itching, tingling, pain etc.) should precede herpes labialis lesions in at least 50% of the previous herpes episodes
  • Good general health (ECOG < 2), immunocompetent
  • Signed and dated written informed consent - Women of childbearing potential must have effective contraception method

Exclusion Criteria:

  • More than 50% of recurrences that aborted spontaneously in the past 12 months
  • Primary herpes lesion outside the lips (e.g. nose, chin, etc.)
  • Abnormal peri-oral skin condition that might affect the normal course of cold sores (e.g. eczema, psoriasis…)
  • Oral diseases whose prodromal symptoms may mimick those of herpes labialis, including recurrent oral aphthous disease
  • Oral diseases that might interfere with the evaluation of the efficacy or safety of the treatments, including gingivitis, parondotis, mucositis, oropharyngeal candidiasis…
  • History of infection known to be resistant to acyclovir family agents
  • Previous vaccination against herpes
  • Concomitant treatment likely to interfere with acyclovir
  • Allergy to any acyclovir containing agents
  • Immunocompromised condition, including HIV+
  • Unability to properly understand protocol requirements, to follow the study procedures, to complete the patient diary or to start the self-initiation of the treatment
  • Upper full or partial dentures with acrylic border in the canine fossa
  • Milk allergy or known history of hypersensitivity to one of the components of the products
  • Rare hereditary problems of galactose intolerance.
  • Lactase enzyme deficiency or glucose galactose malabsorption
  • Clinically significant abnormal level of serum creatinine
  • Patients whose occupations make them unlikely to return to the clinic within 24h of treatment initiation
  • Pregnancy or breast-feeding
  • Investigational drug or immunomodulator treatment in the 30 days prior randomisation
  • Prior enrollment in this study
  • Participation in another therapeutic trial evaluating new drugs or which could interfere with the evolution of herpes labialis or the evaluation of the drug in the study within preceding 30 day.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00769314

  Hide Study Locations
United States, Arizona
Radiant Research, Inc.,
Scottsdale, Arizona, United States, 85251
Radiant Research, Inc.,
Tucson, Arizona, United States, 85710
United States, California
Dermatology Private Practice
San Fransisco, California, United States, 94114
United States, Colorado
Front Range Clinical Research
Wheat Ridge, Colorado, United States, 80033
United States, Idaho
St. Luke's Family Health,
Meridian, Idaho, United States, 83642
United States, Missouri
Clinvest, a Division of Banyan Group, Inc.,
Springfield, Missouri, United States, 65807
United States, New York
Rochester Clinical Research, Inc.,
Rochester, New York, United States, 14609
Stony Brook University Medical Center
Stony Brook, New York, United States, 11794-8091
United States, Texas
Center for Clinical Studies
Houston, Texas, United States, 77030
Center for Clinical Studies, Ltd., LLP.
Houston, Texas, United States, 77058
Taylor Square Private Clinic
Sydney, Australia, Darlinghurst, NSW 2010
Central Brunswick Medical Centre
Sydney, Australia, QLD 4006
Czech Republic
General Teaching Hospital, Dep. Of Dermatology
Opava, Czech Republic, 128 08 Praha 2
U zastavky 16
Opava, Czech Republic, 747 00
Central military hospital Dept. of Dermatology
Praha, Czech Republic, 169 02 Praha 6
University Hospital Bulovka 3rd Clinic of Inf. Diseases
Praha, Czech Republic, 180 81 Praha 8
University Hospital Bulovka Dept. of Dermatology
Praha, Czech Republic, 180 81 Praha 8
Hôpital St Jacques Service de Dermatologie
Besancon, France, 25030 BESANCON CEDEX
Private Practice
Martigues, France, 13500
Hopital Fournier, Service de dermatologie
Nancy, France, 54000
Private Practice
Nice, France, 06000
Hôpital L'Archet 2, Service de Dermatologie
Nice, France, 06202 NICE Cedex
Private Practice
Paris, France, 75005
Hôpital Tenon, Dermatology department
Paris, France, 75020
Hôpital Saint Louis Paris, Service de Dermatologie 1
Paris, France, 75475 PARIS Cedex 10
Service de Stomatologie et chirurgie Maxilo-Faciale.Hôpital de la pitié Salpétrière
Paris, France, 75651 Paris Cedex 13
Hôpital Nord, Service de dermatologie
St. Etienne, France, 42065 St ETIENNE Cedex 2
Tours, France, 37044 TOURS Cedex
Praxis Dres. Dörzapf und Partner
Augsburg, Germany, 86153
Charité Universitätsmedizin Berlin Klinik für Dermatologie, Venerologie und Allergologie
Berlin, Germany, 10117
Berlin, Germany, 10789
Polikum Friedenau
Berlin, Germany, 12157
Berlin, Germany, 12353
Laserclinic Drs. Steinert
Biberach, Germany, 88400
Klinik und Poliklinik für Dermatologie des Universitätsklinikums Bonn
Bonn, Germany, 53105
Frankfurt, Germany, 60326
Raiffeisenstr. 15b
Oberkirch, Germany, 77704
Ludwig-Erhard-Platz 9-11
Rodgau-Dudenhofen, Germany
Katedra i Klinika Dermatologii Collegium Medicum
Bydgoszcz, Poland, 85-096
Centrum Medyczne Diabet
Chrzanów, Poland, 32-500
Naukowo-Badawczy i Naukowo-Dydaktyczny Ośrodek Dermatologii Estetycznej, Dermatochirurgii i Fotodermatologii
Gdynia, Poland, 81-366
Niepubliczny Zaklad Opieki Zdrowotnej GCP Dobra Praktyka Lekarska
Grudziądz, Poland, 86-300
NZOZ Atopia, Al. J.
Kraków, Poland, 31-159
Niepubliczny Zakład Opieki Zdrowotnej Specjalistyczna Przychodnia Lekarska Medikard
Płock, Poland, 09-402
Niepubliczny Zakład Opieki Zdrowotnej "Nasz Lekarz" Praktyka Grupowa Lekarzy Rodzinnych z Przychodnią Specjalistyczną
Toruń, Poland, 87-100
Gabinet Internistyczny
Warszawa, Poland, 03-003
NZOZ Praktyka Lekarska Iga Gilas - Mirkiewicz
Wrocław, Poland, 50-354
Specjalistyczne Gabinety Lekarskie Dermed
Łódź, Poland, 90-265
United Kingdom
Cossington House Surgery
Canterbury, United Kingdom, CT1 3HX
School of Dentistry, Cardiff University
Cardiff, United Kingdom, CF14 4XN
Sidley Surgery
East Sussex, United Kingdom, TN39 5HE
Sea Road Surgery
East Sussex, United Kingdom, TN40 1JJ
Saltash Health Centre
Saltash, United Kingdom, PL12 6DL
Sponsors and Collaborators
  More Information

Responsible Party: Onxeo Identifier: NCT00769314     History of Changes
Other Study ID Numbers: BA2005/21/02
Study First Received: October 8, 2008
Results First Received: October 26, 2011
Last Updated: November 21, 2012

Additional relevant MeSH terms:
Herpes Labialis
Herpes Simplex
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Lip Diseases
Mouth Diseases
Stomatognathic Diseases
Skin Diseases, Infectious
Skin Diseases
Antiviral Agents
Anti-Infective Agents processed this record on May 25, 2017